Philogen S.p.a.

Bayer Schering Pharma Ag

Sirius-biotech S.r.l.

Laura Borsi

Luciano Zardi

Barbara Carnemolla

Dario Neri

Fredrik Nilsson

Lorenzo Tarli

Cornelia Halin

Patrizia Castellani

Enrica Balza

Christoph-Stephan Hilger

Matthias Friebe

Francesca Sassi

M Barbara Carnemolla

Treatment of lesions of pathological angiogenesis, especially tumors, rheumatoid arthritis, diabetic retinopathy, age-related muscular degeneration, and angiomas. A conjugate is used comprising a molecule that exerts a biocidal or cytotoxic effect on target cells in the lesions and an antibody directed against an extracellular matrix component which is present in such lesions. The antibody may be directed against fibronectin-2 (IL-2), doxorubicin, interleukin-12 (IL-12), Interferon-&#x3b3; (IFN-&#x3b3;), Tumor Necrosis Factor &#x3b1; (TNF&#x3b1;) or Tissue Factor protein (which may be truncated).

Compositions and methods for treatment of angiogenesis in pathological lesions

Epitopes localized on FNIII-repeat that are normally cryptic but are unmasked by insertion of FNIII-B into the FN molecule and are recognized by specific ligands are described; antibodies or their fragments able to identify the above said epitope are also described.

Monoclonal antibody and its use for the identification of the oncofetal isoform of fibronectin (B-FN) for diagnosis or therapy

Treatment of lesions of pathological angiogenesis, especially tumors, rheumatoid arthritis, diabetic retinopathy, age-related muscular degeneration. and angiomas. A conjugate is used comprising a molecule that exerts a biocidal or cytotoxic effect on target cells in the lesions and an antibody directed against an extracellular matrix component which is present in such lesions. The antibody may be directed against fibronectin-2 (IL-2), doxorubicin, interleukin-12(IL-12), Interferon-&#x3b3; (IFN-&#x3b3;), Tumor Necrosis Factor &#x3b1;(TNF&#x3b1;) or Tissue Factor protein (which may be truncated).

The present invention relates to selectively targeting tumoral vasculature in vivo using a human recombinant scFv, L19, to the angiogenesis marker ED-B domain of fibronectin. In preferred embodiments, a complete human IgG1 is employed having the variable regions of L19. In other preferred embodiments is employed a mini-immunoglobulin generated by fusing the scFv L19 to the constant CH4 domain of a secretory IgE isoform that naturally contains a cysteine in its COOH terminal and which forms a covalently linked dimer. Different in vivo behavior of the antibody formats is exploitable for different diagnostic and/or therapeutic purposes, depending on clinical needs and disease. The antibody molecules may be labelled as described.

Selective targeting of tumor vasculature using antibody molecules

Growing community of inventors

Genoa, Italy

Laura Borsi